Oncorena is aiming to save human lives by transforming a natural substance into a breakthrough therapy treatment for advanced kidney cancer. We have completed all preclinical studies and are moving into  early-stage clinical development. The objective is to confirm the powerful anti-tumor activity of our drug candidate - based on the natural substance orellanine - in advanced kidney cancer patients. Oncorena AB is headquartered in Lund, Sweden.

Biotechnology

Health Care

Therapeutics

Oncorena AB

Oncorena AB's headquarters in Helsingborg, Sweden

Description

People (2)

Börje Haraldsson

Lisa Buvall

Jobs